Ann: First Patient Treated in BTX 1308 Psoriasis Patient Study, page-23

"Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12-week timeframe. The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 study in June 2018 with completion expected in mid-2019. The BTX 1204 Phase 1b atopic dermatitis patient study concluded in June 2018 and a Phase 2 study is due to commence in December 2018. The BTX 1308 Phase 1b psoriasis patient study commenced in September 2018." 

I suspect something is around the corner ....